EUVIMEDTutustu EUVIMEDiin
Editorial

Editorial: Are we facing an efficacy–effectiveness gap in pediatric psychopharmacology?

Michael H Bloch iD

Journal of Child Psychology and Psychiatry · 2026-12 · 67 (12) · 1933-1936

DOI: 10.1111/jcpp.70252 ↗

At a glance

Editorial in Journal of Child Psychology and Psychiatry, published online on 2026-10-28. Written by Michael H Bloch. Institution: Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. Major MEDLINE topics: Psychopharmacology, Mental Disorders, Pediatrics. 18 references. Funded by: NeuroThera Labs, Emalex Biosciences, Janssen Pharmaceuticals.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

The efficacy–effectiveness gap, the attenuation of benefits as interventions move from controlled trials into routine care, has received substantial focus when scrutinizing psychological interventions but has received less attention in pediatric psychopharmacology. Medication trials evaluate more than molecules: they embed systematic titration, frequent assessment, multi‐informant feedback, and adherence support. This Editorial examines whether differences between trial‐based and routine medication management create a comparable gap. Examples from stimulant treatment in the MTA, antidepressant protocols in TADS and TORDIA, and metabolic surveillance during antipsychotic treatment illustrate how dosing, follow‐up, and safety monitoring may diverge in practice, potentially altering both efficacy and the overall benefit–risk balance. Research should characterize how medications are delivered in routine care and identify which elements of trial‐based management materially improve outcomes. Disseminating evidence‐based pediatric psychopharmacology may require preserving essential medication‐management processes while recognizing constraints faced in practice.

Subjects

MeSH terms (MEDLINE)

PsychopharmacologyMental DisordersPediatricsHumansChild

Author keywords

Psychopharmacologyimplementation and research design

Authors and institutions

  • Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID profiles: Michael H Bloch

Funding

  • NeuroThera Labs
  • Emalex Biosciences
  • Janssen Pharmaceuticals
  • Neurocrine Biosciences
  • NIH HHS
  • Janssen Pharmaceutica
  • National Institutes of Health

Cite

APA

Bloch, M. H. (2026). Editorial: Are we facing an efficacy–effectiveness gap in pediatric psychopharmacology?. Journal of Child Psychology and Psychiatry, 67(12), 1933-1936. https://doi.org/10.1111/jcpp.70252

Vancouver

Bloch MH. Editorial: Are we facing an efficacy–effectiveness gap in pediatric psychopharmacology?. Journal of Child Psychology and Psychiatry. 2026;67(12):1933-1936. doi:10.1111/jcpp.70252

BibTeX
@article{Bloch2026,
  author = {Bloch, Michael H},
  title = {Editorial: Are we facing an efficacy–effectiveness gap in pediatric psychopharmacology?},
  journal = {Journal of Child Psychology and Psychiatry},
  year = {2026},
  volume = {67},
  number = {12},
  pages = {1933--1936},
  doi = {10.1111/jcpp.70252}
}
Start for free →